8-K: NKGen Biotech Issues Second Tranche Warrant and Note to AJB Capital Investments

NKGen Biotech has issued a second tranche of a common stock purchase warrant and promissory note to AJB Capital Investments, as part of a previously disclosed securities purchase agreement.

Summary

• NKGen Biotech issued a second promissory note with a principal amount of $369,600 to AJB Capital Investments, with a purchase price of $300,000, resulting in a $69,600 original issue discount.
• The note is unsecured, has a 12-month term, and matures on June 18, 2025, with no interest payable other than default interest.
• AJB has the right to convert the outstanding principal into shares of common stock at a conversion price of $2.00 per share, subject to adjustments.
• A second common stock purchase warrant was also issued to AJB, allowing the purchase of up to 330,000 shares of common stock at an exercise price of $2.00 per share, also subject to adjustments, for a period of five years.
• The company may issue up to two additional promissory notes and warrants under the same terms at AJB's discretion, for a total of $739,200 and 660,000 shares respectively.

Sentiment

Score: 4

Explanation: The document indicates a necessary but dilutive financing event. While the funding is positive for the company's operations, the terms, including the original issue discount and potential dilution, are negative for existing shareholders. The complexity of the terms and the potential for penalties also contribute to a lower sentiment score.

Positives

• The agreement provides NKGen Biotech with additional funding.
• The warrants provide potential future capital if exercised.
• The structure allows for flexibility with potential future tranches.

Negatives

• The promissory note includes a significant original issue discount of $69,600.
• The conversion of the note and exercise of warrants could dilute existing shareholders.
• The company is obligated to issue shares upon conversion or exercise, potentially impacting share price.

Risks

• The company's failure to deliver shares on time could result in penalties and be considered an event of default.
• The conversion price and exercise price are subject to adjustments, which could lead to further dilution.
• The company's ability to issue shares under the warrants is limited without shareholder approval.
• The company is subject to various covenants and restrictions under the note and warrant agreements.

Future Outlook

The company may issue up to two additional tranches of promissory notes and warrants under the same terms at AJB's discretion, for a total of $739,200 and 660,000 shares respectively, indicating potential for further funding and dilution.

Industry Context

This type of financing, involving promissory notes and warrants, is common for small-cap biotech companies seeking capital. The terms, including the original issue discount and potential dilution, are typical for such agreements.

Comparison to Industry Standards

• The use of warrants and convertible notes is a standard practice for biotech companies seeking funding, especially those with limited revenue.
• The original issue discount of approximately 18.8% is within the typical range for such financings, reflecting the risk associated with the investment.
• The conversion and exercise prices of $2.00 per share are common for companies with a low share price, and the adjustment clauses are designed to protect the investor from dilution.
• Similar companies such as XORTX Therapeutics Inc. and Athersys Inc. have used similar financing methods, including convertible notes and warrants, to raise capital.

Stakeholder Impact

• Shareholders may experience dilution due to the potential conversion of the note and exercise of warrants.
• The company's employees may benefit from the additional funding, which could support operations and growth.
• Creditors may be impacted by the terms of the note, which could affect the company's ability to repay other debts.

Next Steps

• The company needs to ensure timely delivery of shares upon conversion or exercise to avoid penalties.
• The company needs to monitor the share price and potential dilution from the conversion and exercise of warrants.
• The company may need to seek shareholder approval to issue additional shares if the Exchange Cap is reached.

Key Dates

Keywords

warrant, promissory note, common stock, AJB Capital Investments, conversion, exercise price, dilution, financing, securities purchase agreement, NKGen Biotech